/ Medical Professionals

Pipeline

Rigorous and groundbreaking science has always been at the core of what we do at Genentech. Our R&D activities are focused on applying excellent science to discover and develop potential new medicines with the goal of becoming first-in-class or best-in-class therapeutics.


Displaying
45
MOLECULES
  • Oncology
  • Immunology
  • Neuroscience
  • Metabolism
  • Infectious Disease
  • Ophthalmology
       
Managed by Roche
Molecule Indication Phase
Alectinib ALK+ metastatic non-small cell lung cancer
Anti-ETBR Antibody drug conjugate Melanoma
Anti-HER3/EGFR DAF MAb Head and neck cancer
Colorectal cancer
Anti-Mesothelin Antibody drug conjugate Pancreatic and ovarian cancers
Anti-MUC16 Antibody drug conjugate

Ovarian cancer

Anti-NaPi2b Antibody drug conjugate Platinum-sensitive ovarian cancer
Platinum-resistant ovarian cancer
Non-small cell lung cancer and ovarian cancer
Anti-PDL1 MAb Solid tumors *
Metastatic melanoma *
Anti-STEAP1 Antibody drug conjugate

Prostate Cancer

Antibody drug conjugate Pancreatic and ovarian cancers
Antibody drug conjugate Solid Tumors
Bcl-2 Inhibitor (GDC-0199/ABT199)

Chronic lymphocytic leukemia and non-Hodgkin's lymphoma

*
Bevacizumab

1st line glioblastoma multiforme

*

1st line metastatic ovarian cancer

*

Adjuvant breast cancer, HER2-negative

*

Adjuvant breast cancer, HER2-positive

*

Adjuvant non-small cell lung cancer

*

High-risk carcinoid

*
ChK1 Inhibitor (GDC-0575)

Solid tumors or lymphoma

Cobimetinib (MEK Inhibitor, GDC-0973)

Solid tumors

Metastatic melanoma

*
ERK Inhibitor (GDC-0994) Solid tumors
Erlotinib

1st line metastatic non-small cell lung cancer, EGFR mutation positive

*
Ipatasertib (Akt Inhibitor) Solid tumors
Gastric cancer
Prostate cancer
New molecular entity (GDC-0853) Hematologic malignancies
Obinutuzumab

Diffuse large B-cell lymphoma

*

Front-line indolent non-Hodgkin's lymphoma

*

Refractory indolent Non Hodgkin's lymphoma

*

Front-line chronic lymphocytic leukemia

*
Onartuzumab

metastatic colorectal cancer

*

metastatic non-small cell lung cancer

*

Avastin-naïve recurrent glioblastoma

*

1st line non-squamous non-small cell lung cancer

*

1st line squamous non-small cell lung cancer

*

metastatic HER2-negative gastric cancer

*

triple negative metastatic breast cancer

*
Pertuzumab

Early HER2-positive breast cancer

*

HER2-positive gastric cancer

*

2nd line HER2-positive metastatic breast cancer

*
PI3 Kinase Inhibitor (GDC-0084)

Glioma

Pictilisib (PI3 Kinase Inhibitor) ER+ metastatic breast cancer *
Metastatic HER2-/HR+ breast cancer *
Metastatic non-small cell lung cancer *
Pinatuzumab vedotin (Anti-CD22 ADC) Non-Hodgkin's lymphoma and diffuse large B-cell lymphoma
Polatuzumab vedotin (Anti-CD79b ADC) Non-Hodgkin's lymphoma and diffuse large B-cell lymphoma *
Taselisib (PI3 Kinase Inhibitor) HER2-negative metastatic breast cancer *
Solid tumors and HR+ breast cancer *
Trastuzumab emtansine (T–DM1)

1st line HER2-positive metastatic breast cancer

*

3rd line HER2-positive metastatic breast cancer

*
Vemurafenib

Adjuvant metastatic melanoma, BRAF mutation positive

*

Papillary thyroid cancer, BRAF mutation positive

*

Metastatic melanoma, BRAF mutation positive

*
Vismodegib

Operable basal cell carcinoma

*
Anti-IL17 Autoimmune disease
Etrolizumab Ulcerative colitis
Lampalizumab Geographic atrophy associated with age-related macular degeneration *
Lebrikizumab

Severe asthma

*
Omalizumab Chronic idiopathic urticaria *
Quilizumab Chronic spontaneous urticaria
Allergic asthma 
Sodium Hyaluronate

Enthesopathy

*
Tocilizumab Early rheumatoid arthritis *
Systemic sclerosis *
Arbaclofen

Fragile X syndrome

*
Bitopertin

Schizophrenia; suboptimally controlled symptom

*

Schizophrenia; persistent, predominant negative symptoms

*
Crenezumab Alzheimer's Disease
Ocrelizumab

Primary progressive multiple sclerosis

*

Relapsing multiple sclerosis

*
Tofogliflozin

Type 2 diabetes

*
Anti-CMV

Cytomegalovirus disease in kidney transplant recipients

Anti-Influenza A Influenza
Ranibizumab

Sustained delivery age-related macular degeneration/retinal vein occlusion/diabetic macular edema

*
No molecules match your search.

Accessing Investigational Medicines

Learn how patients gain access to medicines before they are FDA-approved.

Partner with Us

Approximately 50% of our pipeline and marketed products involve some kind of collaboration.